SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. 3rd ed. Lyon, France: IARC Press; 2001.
  • 2
    Ben-Ezra J, Burke JS, Swartz WG, et al. Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood. 1989; 73: 579-587.
  • 3
    Coiffier B, Thieblemont C, Felman P, Salles G, Berger F. Indolent nonfollicular lymphomas: characteristics, treatment, and outcome. Semin Hematol. 1999; 36: 198-208.
  • 4
    Landgren O, Tilly H. Epidemiology, pathology and treatment of non-follicular indolent lymphomas. Leuk Lymphoma. 2008; 49( 1 suppl): 35-42.
  • 5
    Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kittas C. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol. 1999; 36: 104-114.
  • 6
    Papamichael D, Norton AJ, Foran JM, et al. Immunocytoma: a retrospective analysis from St Bartholomew's Hospital—1972 to 1996. J Clin Oncol. 1999; 17: 2847-2853.
  • 7
    Seng JE, Peterson BA. Indolent B-cell non-Hodgkin's lymphomas. Oncology (Williston Park). 1997; 11: 1883-1894.
  • 8
    Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: recent advances in biology and therapy. Clin Adv Hematol Oncol. 2009; 7: 677-690.
  • 9
    Treon SP. How I treat Waldenstrom macroglobulinemia. Blood. 2009; 114: 2375-2385.
  • 10
    Zinzani PL. Traditional treatment approaches in B-cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2003; 44( 4 suppl): S6-S14.
  • 11
    Baldini L, Brugiatelli M, Luminari S, et al. Treatment of indolent B-cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol. 2003; 21: 1459-1465.
  • 12
    Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1750-1757.
  • 13
    Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996; 347: 1432-1438.
  • 14
    Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001; 98: 2319-2325.
  • 15
    Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007; 370: 230-239.
  • 16
    Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107: 885-891.
  • 17
    Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007; 25: 793-798.
  • 18
    Dimopoulos MA, Hamilos G, Efstathiou E, et al. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma. 2003; 44: 993-996.
  • 19
    Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000; 96: 71-75.
  • 20
    Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up—a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000; 18: 987-994.
  • 21
    Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer. 2004; 100: 2181-2189.
  • 22
    Ferrario A, Merli F, Luminari S, et al. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol. 2011; 90: 323-330.
  • 23
    Montoto S, Moreno C, Domingo-Domenech E, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica. 2008; 93: 207-214.
  • 24
    Vitolo U, Boccomini C, Ladetto M, et al. Rituximab (R) maintenance versus observation after short term chemoimmunotherapy R-FND as first line treatment in elderly patients with advanced follicular lymphoma (FL): updated results and safety of the maintenance of an Intergruppo Italiano Linfomi (IIL) randomized trial [ASH Annual Meeting Abstracts]. Blood. 2009; 114. Abstract 706.
  • 25
    Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007; 99: 706-714.
  • 26
    Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4079-4088.
  • 27
    Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010; 28: 1756-1765.
  • 28
    Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112: 975-980.
  • 29
    Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4070-4078.
  • 30
    Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-1174.
  • 31
    Dimopoulos MA, Kastritis E, Roussou M, et al. Rituximab-based treatments in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009; 9: 59-61.
  • 32
    Peinert S, Tam CS, Prince HM, et al. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2010; 51: 2188-2197.
  • 33
    Sacchi S, Pozzi S, Marcheselli R, et al. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer. 2007; 110: 121-128.
  • 34
    Tam CS, Wolf M, Prince HM, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer. 2006; 106: 2412-2420.
  • 35
    Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 4261-4267.
  • 36
    Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004; 103: 4416-4423.
  • 37
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244-1244.
  • 38
    Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy [abstract]. J Clin Oncol. 2010; 28( 15s). Abstract 8004.
  • 39
    van Oers MH, van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010; 28: 2853-2858.
  • 40
    Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009; 145: 741-748.
  • 41
    Tam CS, Seymour JF, Prince HM, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica. 2006; 91: 1546-1550.
  • 42
    Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003; 21: 897-906.
  • 43
    Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001; 7: 3580-3589.